Allstate Corp Acquires Shares of 1,176 United Therapeutics Co. (NASDAQ:UTHR)

Allstate Corp bought a new position in United Therapeutics Co. (NASDAQ:UTHR) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 1,176 shares of the biotechnology company’s stock, valued at approximately $415,000.

Other institutional investors have also recently made changes to their positions in the company. Wealthfront Advisers LLC boosted its holdings in United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares during the last quarter. Norges Bank bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $151,764,000. World Investment Advisors LLC purchased a new position in shares of United Therapeutics in the 3rd quarter worth approximately $139,206,000. Thrivent Financial for Lutherans grew its holdings in shares of United Therapeutics by 1,325.5% in the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock valued at $72,085,000 after acquiring an additional 189,967 shares in the last quarter. Finally, AustralianSuper Pty Ltd increased its position in shares of United Therapeutics by 577.1% during the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock valued at $66,962,000 after acquiring an additional 161,751 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Activity

In other news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $929,678.52. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,500 shares of company stock worth $26,134,500. 11.90% of the stock is owned by company insiders.

United Therapeutics Trading Up 1.8 %

United Therapeutics stock opened at $312.26 on Thursday. The firm has a market capitalization of $14.02 billion, a price-to-earnings ratio of 13.71, a P/E/G ratio of 0.97 and a beta of 0.64. The firm has a 50 day simple moving average of $336.64 and a 200 day simple moving average of $355.09. United Therapeutics Co. has a 1-year low of $227.75 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the business earned $4.36 earnings per share. On average, equities research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on UTHR shares. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. UBS Group boosted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.